À propos de la propriété intellectuelle Formation en propriété intellectuelle Respect de la propriété intellectuelle Sensibilisation à la propriété intellectuelle La propriété intellectuelle pour… Propriété intellectuelle et… Propriété intellectuelle et… Information relative aux brevets et à la technologie Information en matière de marques Information en matière de dessins et modèles industriels Information en matière d’indications géographiques Information en matière de protection des obtentions végétales (UPOV) Lois, traités et jugements dans le domaine de la propriété intellectuelle Ressources relatives à la propriété intellectuelle Rapports sur la propriété intellectuelle Protection des brevets Protection des marques Protection des dessins et modèles industriels Protection des indications géographiques Protection des obtentions végétales (UPOV) Règlement extrajudiciaire des litiges Solutions opérationnelles à l’intention des offices de propriété intellectuelle Paiement de services de propriété intellectuelle Décisions et négociations Coopération en matière de développement Appui à l’innovation Partenariats public-privé Outils et services en matière d’intelligence artificielle L’Organisation Travailler avec nous Responsabilité Brevets Marques Dessins et modèles industriels Indications géographiques Droit d’auteur Secrets d’affaires Académie de l’OMPI Ateliers et séminaires Application des droits de propriété intellectuelle WIPO ALERT Sensibilisation Journée mondiale de la propriété intellectuelle Magazine de l’OMPI Études de cas et exemples de réussite Actualités dans le domaine de la propriété intellectuelle Prix de l’OMPI Entreprises Universités Peuples autochtones Instances judiciaires Ressources génétiques, savoirs traditionnels et expressions culturelles traditionnelles Économie Financement Actifs incorporels Égalité des genres Santé mondiale Changement climatique Politique en matière de concurrence Objectifs de développement durable Technologies de pointe Applications mobiles Sport Tourisme PATENTSCOPE Analyse de brevets Classification internationale des brevets Programme ARDI – Recherche pour l’innovation Programme ASPI – Information spécialisée en matière de brevets Base de données mondiale sur les marques Madrid Monitor Base de données Article 6ter Express Classification de Nice Classification de Vienne Base de données mondiale sur les dessins et modèles Bulletin des dessins et modèles internationaux Base de données Hague Express Classification de Locarno Base de données Lisbon Express Base de données mondiale sur les marques relative aux indications géographiques Base de données PLUTO sur les variétés végétales Base de données GENIE Traités administrés par l’OMPI WIPO Lex – lois, traités et jugements en matière de propriété intellectuelle Normes de l’OMPI Statistiques de propriété intellectuelle WIPO Pearl (Terminologie) Publications de l’OMPI Profils nationaux Centre de connaissances de l’OMPI Série de rapports de l’OMPI consacrés aux tendances technologiques Indice mondial de l’innovation Rapport sur la propriété intellectuelle dans le monde PCT – Le système international des brevets ePCT Budapest – Le système international de dépôt des micro-organismes Madrid – Le système international des marques eMadrid Article 6ter (armoiries, drapeaux, emblèmes nationaux) La Haye – Le système international des dessins et modèles industriels eHague Lisbonne – Le système d’enregistrement international des indications géographiques eLisbon UPOV PRISMA UPOV e-PVP Administration UPOV e-PVP DUS Exchange Médiation Arbitrage Procédure d’expertise Litiges relatifs aux noms de domaine Accès centralisé aux résultats de la recherche et de l’examen (WIPO CASE) Service d’accès numérique aux documents de priorité (DAS) WIPO Pay Compte courant auprès de l’OMPI Assemblées de l’OMPI Comités permanents Calendrier des réunions WIPO Webcast Documents officiels de l’OMPI Plan d’action de l’OMPI pour le développement Assistance technique Institutions de formation en matière de propriété intellectuelle Mesures d’appui concernant la COVID-19 Stratégies nationales de propriété intellectuelle Assistance en matière d’élaboration des politiques et de formulation de la législation Pôle de coopération Centres d’appui à la technologie et à l’innovation (CATI) Transfert de technologie Programme d’aide aux inventeurs WIPO GREEN Initiative PAT-INFORMED de l’OMPI Consortium pour des livres accessibles L’OMPI pour les créateurs WIPO Translate Speech-to-Text Assistant de classification États membres Observateurs Directeur général Activités par unité administrative Bureaux extérieurs Avis de vacance d’emploi Achats Résultats et budget Rapports financiers Audit et supervision
Arabic English Spanish French Russian Chinese
Lois Traités Jugements Recherche par ressort juridique

Décision n° 30/2006/QD BYT du 30 septembre 2006 portant promulgation du règlement sur la sécurité des données concernant les dossiers d'homologation des médicaments, Viet Nam

Retour Texte abrogé 
Détails Détails Année de version 2006 Dates Entrée en vigueur: 11 novembre 2006 Adopté/e: 30 septembre 2006 Type de texte Textes règlementaires Sujet Information non divulguée (Secrets commerciaux), Divers Notes La notification présentée par le Viet Nam à l’OMC au titre de l’article 63.2 de l’Accord sur les ADPIC indique ce qui suit :
'La décision porte promulgation de règlements relatifs à la protection des données appliquée aux dossiers d'homologation des médicaments (confidentialité des données résultant d'essais communiquées dans le cadre de procédures concernant l'autorisation de la commercialisation de médicaments.'

Documents disponibles
Texte(s) principal(aux) Textes connexe(s)
Texte(s) princip(al)(aux) Texte(s) princip(al)(aux) Anglais Decision No. 30/2006/QD-BYT of September 30, 2006, promulgating the Regulation on Data Security of Drug Registration Records        
 
Télécharger le PDF open_in_new
Decision No. 30/2006/QD-BYT of September 30, 2006, promulgating the Regulation on Data Security of Drug Registration Records

DECISION No. 30/2006/QD-BYT OF SEPTEMBER 30, 2006, PROMULGATING THE

REGULATION ON DATA SECURITY OF DRUG REGISTRATION RECORDS

THE MINISTER OF HEALTH

Pursuant to the June 14, 2005 Pharmacy Law;

Pursuant to the November 29, 2005 Intellectual Property Law;

Pursuant to the Government’s Decree No. 103/2006/ND-CP of September 22, 2006, detailing and guiding the implementation of a number of articles of the Intellectual Property Law regarding industrial property;

Pursuant to the Government’s Decree No. 49/2003/ND-CP of May 15, 2003, defining the functions, tasks, powers and organizational structure of the Ministry of Health;

Pursuant to Official Letter No. 200/UB-VP of September 22, 2006, of the National Committee for International Economic Cooperation, notifying the results of negotiations with the United States on the protection of test data;

At the proposal of the Director of the Vietnam Drug Administration,

DECIDES:

Article 1.- To promulgate together with this Decision the Regulation on data security of drug registration records.

Article 2.- This Decision takes effect 15 days after its publication in “CONG BAO.”

Article 3.- The director of the Office and the director of the Inspectorate of the Health Ministry, the directors of the Vietnam Drug Administration and the Preventive Medicine Department, heads of units under the Health Ministry, directors of provincial/municipal Health Services, and heads of concerned drug-trading establishments, testing establishments and medical treatment establishments shall implement this Decision.

Minister of Health

TRAN THI TRUNG CHIEN

REGULATION ON DATA SECURITY OF DRUG REGISTRATION RECORDS

GENERAL PROVISIONS

Article 1.- Scope of regulation and subjects of application

1. Scope of regulation: This Regulation provides the order and procedures related to the security of data of drug registration records.
2. Subjects of application: This Regulation applies to domestic and foreign organizations and individuals that carry out drug registration procedures in Vietnam and to concerned agencies in charge of state management of pharmacy.

Article 2.- Interpretation of terms

In this Regulation, the terms below are construed as follows:
1. Drug means a substance or a mixture of substances for human use for the purposes of disease prevention, treatment or diagnosis or rehabilitation of human physical functions, including finished drugs, drug materials, vaccines and medical biologicals, except functional foodstuff.
2. Pharmaceutical substance (also referred to as active ingredient) means a substance or a mixture of substances having treatment active-ingredients which are used in drug manufacture.
3. New drug means a drug containing a new pharmaceutical substance or drug with a new combination of circulated pharmaceutical substances.
4. Clinical drug test means a scientific research into drugs on humans in a systematic manner with a view to verifying clinical efficiency, identifying and discovering harmful effects of the researched products; the ability of such products to absorb, distribute, transform or discharge, aiming to determine the safety and effectiveness of drugs.
5. Additional indication, formula or preparation form means a new indication, new formula or new preparation form of a new drug which has been granted a circulation registration number.
6. Business secret means information received from financial investment or intellectual activities which has not been revealed and can be used in business activities.
7. Data security means the application of necessary measures to ensure that data are neither used for unhealthy commercial purposes nor revealed, unless when the revelation is necessary for the protection of people.

Article 3.- Types of data to be secured

1. Test results related to toxicity and clinical drug test data of new drugs which have never been publicized or revealed.
2. Other data (except additional indications, formulas and preparation forms) which meet the conditions specified in Article 4 of this Regulation.

Article 4.- Conditions for data to be secured

Data to be secured must fully meet the following conditions:
1. Being business secrets.
2. Being results of investment of significant efforts.
3. Being supplied by drug-registering establishments under current regulations on drug registration.
4. Being requested to be secured by drug-registering establishments under the provisions of Article 5 of this Regulation.

Article 5.- Required documents for data security consideration

1. Required documents include:
a/ An application for enforcement of data security (made according to a set form);
b/ A document proving that data which need be secured fully meet the conditions specified in
Clause 1, Article 4 of this Regulation.
c/ A document proving that data which need be secured are under lawful ownership of the drug- registering establishment which requests the enforcement of data security.
2. The application for enforcement of data security and proof documents specified in Clause 1 of this Article constitute part of a drug registration dossier and must be submitted together with the dossier. Applications and documents submitted after drug registration dossiers shall not be considered.

Article 6.- Forms of applications and documents related to data security enforcement request

1. An application for enforcement of data security and enclosed documents must be made in Vietnamese or English, signed and stamped for certification by the drug-registering establishment on every page of those documents.
2. Legal documents (diplomas, certificates, etc.) must be originals or copies notarized in Vietnam. Diplomas and certificates which are issued, notarized or authenticated by foreign agencies or organizations must be legalized by consular offices and translated into Vietnamese. The translations must be notarized in accordance with Vietnamese law.
3. Parts of a dossier which contain data to be secured must be sealed and appended with a confidentiality stamp of the drug-registering establishment.
Chapter II
PROCEDURES FOR SUBMISSION AND RECEIPT OF DRUG REGISTRATION DOSSIERS CONTAINING DATA TO BE SECURED

Article 7.- Submission of dossiers

1. A drug registration dossier containing data which need be secured and relevant proof documents shall be submitted directly at the drug circulation-licensing agency or at the place of receipt of dossiers designated by the drug circulation-licensing agency, or shall be sent by registered mail.
2. If, at the time the drug registration dossier is being submitted (or arriving at the drug circulation- licensing agency), the parts of data which need be secured no longer have confidentiality signs or intact seals, the drug circulation-licensing agency shall not be responsible for data security.

Article 8.- Receipt of dossiers

Upon receiving a drug registration dossier containing data which need be secured, the drug circulation-licensing agency shall:
1. Inspect the intactness of the dossier and its confidentiality seal.
2. Check documents in the dossier against those listed in the application for enforcement of data security.
3. Append a stamp on the application and all enclosed documents, certifying the date of receipt of the dossier; and write down necessary information in the dossier receipt book.
4. Temporarily keep data which need be secured according to current regulations until it officially accepts or rejects the application for enforcement of data security.
Chapter III
RESPONSIBILITIES OF THE DRUG CIRCULATION-LICENSING AGENCY

Article 9.- Consideration of and reply to a data security enforcement request

1. Within six months after receiving a drug registration dossier containing data which need be secured, the drug circulation-licensing agency shall evaluate the application for enforcement of data security and relevant documents required in Articles 3, 4, 5 and 6 of this Regulation and notify in writing the drug-registering establishment of its acceptance or rejection of the data security enforcement request.
2. If rejecting a data security enforcement request, the drug circulation-licensing agency shall clearly state the reasons therefor.

Article 10.- Security enforcement and duration

1. For data to be secured, the drug circulation-licensing agency shall take necessary security measures as stipulated in Clause 1, Article 128 of the Intellectual Property Law until those data no longer meet the conditions specified in Article 4 of this Regulation.
2. Except the case defined at Point d, Clause 2, Article 125 of the Intellectual Property Law, within 5 years after the drugs for which the drug registration dossier containing confidential is submitted to the drug circulation-licensing agency are granted circulation permits, the drug circulation-licensing agency may not license any drug-registering establishments which submit later dossiers with the same confidential data without consent of the person who has submitted those data.

Article 11.- Processing of data after security duration

At the end of the security duration stipulated in Article 10 of this Regulation, the submitted data shall be archived by the drug circulation-licensing agency like data which need not be secured.
Chapter IV HANDLING OF VIOLATIONS

Article 12.- Handling of violations

Organizations or individuals that violate the provisions of this Regulation shall, depending on the severity of their violations, be disciplined, administratively sanctioned or examined for penal liability in accordance with law.
Minister of Health

TRAN THI TRUNG CHIEN

Législation Promulgue (1 texte(s)) Promulgue (1 texte(s)) est abrogé(e) par (1 texte(s)) est abrogé(e) par (1 texte(s)) Référence du document de l'OMC
IP/N/1/VNM/U/1
IP/N/1/VNM/U/1 (p. 3-6)
Aucune donnée disponible

N° WIPO Lex VN014